Authors:
FRANCIS DP
GREGORY T
MCELRATH MJ
BELSHE RB
GORSE GJ
MIGASENA S
KITAYAPORN D
PITISUTTITHAM P
MATTHEWS T
SCHWARTZ DH
BERMAN PW
Citation: Dp. Francis et al., ADVANCING AIDSVAX(TM) TO PHASE-3 - SAFETY, IMMUNOGENICITY, AND PLANS FOR PHASE-3, AIDS research and human retroviruses, 14, 1998, pp. 325-331
Authors:
GORSE GJ
MCELRATH MJ
MATTHEWS TJ
HSIEH RH
BELSHE RB
COREY L
FREY SE
KENNEDY DJ
WALKER MC
EIBL MM
Citation: Gj. Gorse et al., MODULATION OF IMMUNOLOGICAL RESPONSES TO HIV-1(MN) RECOMBINANT GP160 VACCINE BY DOSE AND SCHEDULE OF ADMINISTRATION, Vaccine, 16(5), 1998, pp. 493-506
Authors:
CLEMENTSMANN ML
WEINHOLD K
MATTHEWS TJ
GRAHAM BS
GORSE GJ
KEEFER MC
MCELRATH MJ
HSIEH RH
MESTECKY J
ZOLLAPAZNER S
MASCOLA J
SCHWARTZ D
SILICIANO R
COREY L
WRIGHT PF
BELSHE R
DOLIN R
JACKSON S
XU S
FAST P
WALKER MC
STABLEIN D
EXCLER JL
TARTAGLIA J
DULIEGE AM
SINANGIL F
PAOLETTI E
Citation: Ml. Clementsmann et al., IMMUNE-RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 INDUCEDBY CANARYPOX EXPRESSING HIV-1(MN) GP120, HIV-1(SF2) RECOMBINANT GP120, OR BOTH VACCINES IN SERONEGATIVE ADULTS, The Journal of infectious diseases, 177(5), 1998, pp. 1230-1246
Authors:
GRAHAM BS
MCELRATH MJ
CONNOR RI
SCHWARTZ DH
GORSE GJ
KEEFER MC
MULLIGAN MJ
MATTHEWS TJ
WOLINSKY SM
MONTEFIORI DC
VERMUND SH
LAMBERT JS
COREY L
BELSHE RB
DOLIN R
WRIGHT PF
KORBER BT
WOLFF MC
FAST PE
Citation: Bs. Graham et al., ANALYSIS OF INTERCURRENT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTIONS IN PHASE-I AND PHASE-II TRIALS OF CANDIDATE AIDS VACCINES, The Journal of infectious diseases, 177(2), 1998, pp. 310-319
Authors:
KEEFER MC
WOLFF M
GORSE GJ
GRAHAM BS
COREY L
CLEMENTSMANN ML
VERANIKETTER N
ERB S
SMITH CM
BELSHE RB
WAGNER LJ
MCELRATH MJ
SCHWARTZ DH
FAST P
CHARRON K
REYNOLDS MJ
ZIMMERMAN E
JONES K
HARRIS M
FREY SE
KENNEDY DJ
ISRAEL H
BERRY C
READ B
SPITZ T
PACATTE T
DOLIN R
REICHMAN RC
LAMBERT J
DEMETER L
ROBERTS NJ
PUGLIESE M
BERGER D
BURKE J
SCOTT T
BLACKSTONE E
WRIGHT PF
BRAEUNER M
RYBCZYK GK
CRUMBO K
BATTLE W
CORNELL R
OWENS D
JENNINGS M
HARBISON MA
HENSMAN BJ
BARR P
STABLEIN DM
VOSS T
PALLAS S
LOMAX N
KOFF W
LAWRENCE D
JOHNSTON M
SAVARESE B
WESCOTT SL
Citation: Mc. Keefer et al., SAFETY PROFILE OF PHASE-I AND PHASE-II PREVENTIVE HIV TYPE-1 ENVELOPEVACCINATION - EXPERIENCE OF THE NIAID AIDS VACCINE EVALUATION GROUP, AIDS research and human retroviruses, 13(14), 1997, pp. 1163-1177
Citation: Gj. Gorse et al., ANTIBODY TO NATIVE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEINS INDUCED BY IIIB AND MN RECOMBINANT GP120 VACCINES, Clinical and diagnostic laboratory immunology, 3(4), 1996, pp. 378-386
Authors:
GORSE GJ
OTTO EE
POWERS DC
CHAMBERS GW
EICKHOFF CS
NEWMAN FK
Citation: Gj. Gorse et al., INDUCTION OF MUCOSAL ANTIBODIES BY LIVE ATTENUATED AND INACTIVATED INFLUENZA-VIRUS VACCINES IN THE CHRONICALLY ILL ELDERLY, The Journal of infectious diseases, 173(2), 1996, pp. 285-290
Authors:
GORSE GJ
KEEFER MC
BELSHE RB
MATTHEWS TJ
FORREST BD
HSIEH RH
KOFF WC
HANSON CV
DOLIN R
WEINHOLD KJ
FREY SE
KETTER N
FAST PE
Citation: Gj. Gorse et al., A DOSE-RANGING STUDY OF A PROTOTYPE SYNTHETIC HIV-1(MN) V3 BRANCHED PEPTIDE VACCINE, The Journal of infectious diseases, 173(2), 1996, pp. 330-339
Authors:
MASCOLA JR
SNYDER SW
WEISLOW OS
BELAY SM
BELSHE RB
SCHWARTZ DH
CLEMENTS ML
DOLIN R
GRAHAM BS
GORSE GJ
KEEFER MC
MCELRATH MJ
WALKER MC
WAGNER KF
MCNEIL JG
MCCUTCHAN FE
BURKE DS
Citation: Jr. Mascola et al., IMMUNIZATION WITH ENVELOPE SUBUNIT VACCINE PRODUCTS ELICITS NEUTRALIZING ANTIBODIES AGAINST LABORATORY-ADAPTED BUT NOT PRIMARY ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1, The Journal of infectious diseases, 173(2), 1996, pp. 340-348
Authors:
GRAHAM BS
KEEFER MC
MCELRATH MJ
GORSE GJ
SCHWARTZ DH
WEINHOLD K
MATTHEWS TJ
ESTERLITZ JR
SINANGIL F
FAST PE
WRIGHT PF
DOLIN R
COREY L
BELSHE RB
CLEMENTS ML
BOLOGNESI DP
STABLEIN DM
CHERNOFF D
DULIEGE AM
WALKER CM
Citation: Bs. Graham et al., SAFETY AND IMMUNOGENICITY OF A CANDIDATE HIV-1 VACCINE IN HEALTHY-ADULTS - RECOMBINANT GLYCOPROTEIN (RGP)-120 - A RANDOMIZED, DOUBLE-BLIND TRIAL, Annals of internal medicine, 125(4), 1996, pp. 270
Authors:
GORSE GJ
ROGERS JH
PERRY JE
NEWMAN FK
FREY SE
PATEL GB
BELSHE RB
SCHWARTZ DH
CLEMENTS ML
KEEFER M
DOLIN R
MCELRATH J
COREY L
GRAHAM BS
WRIGHT PF
STABLEIN DM
MATTHEWS TJ
BOLOGNESI D
MESTECKY J
WALKER MC
FAST PE
Citation: Gj. Gorse et al., HIV-1 RECOMBINANT GP160 VACCINE-INDUCED ANTIBODIES IN SERUM AND SALIVA, Vaccine, 13(2), 1995, pp. 209-214
Authors:
GORSE GJ
PATEL GB
NEWMAN FK
MANDAVA M
BELSHE RB
Citation: Gj. Gorse et al., RECOMBINANT GP160 VACCINATION SCHEDULE AND MHC HLA TYPE AS FACTORS INFLUENCING CELLULAR-RESPONSES TO HIV-1 ENVELOPE GLYCOPROTEIN, Vaccine, 13(13), 1995, pp. 1170-1179
Authors:
GORSE GJ
CAMPBELL MJ
OTTO EE
POWERS DC
CHAMBERS GW
NEWMAN FK
Citation: Gj. Gorse et al., INCREASED ANTIINFLUENZA-A VIRUS CYTOTOXIC T-CELL ACTIVITY FOLLOWING VACCINATION OF THE CHRONICALLY ILL ELDERLY WITH LIVE ATTENUATED OR INACTIVATED INFLUENZA-VIRUS VACCINE, The Journal of infectious diseases, 172(1), 1995, pp. 1-10
Citation: Gj. Gorse, PHASE I II TRIALS OF PREVENTIVE HIV VACCINE CANDIDATES - DOSE AND SCHEDULE - SUMMARY/, AIDS research and human retroviruses, 10, 1994, pp. 190000141-190000143
Authors:
KEEFER MC
GRAHAM BS
BELSHE RB
SCHWARTZ D
COREY L
BOLOGNESI DP
STABLEIN DM
MONTEFIORI DC
MCELRATH MJ
CLEMENTS ML
GORSE GJ
WRIGHT PF
MATTHEWS TJ
SMITH GE
LAWRENCE D
DOLIN R
Citation: Mc. Keefer et al., STUDIES OF HIGH-DOSES OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RECOMBINANT GLYCOPROTEIN-160 CANDIDATE VACCINE IN HIV TYPE-1-SERONEGATIVE HUMANS, AIDS research and human retroviruses, 10(12), 1994, pp. 1713-1723
Authors:
GORSE GJ
FREY SE
PATEL G
NEWMAN FK
BELSHE RB
SCHWARTZ D
CLEMENTS ML
KEEFER M
ROBERTS N
DOLIN R
MCELRATH J
COREY L
GRAHAM BS
WRIGHT P
MATTHEWS T
BOLOGNESI D
WALKER MC
FAST P
FERNIE BF
Citation: Gj. Gorse et al., VACCINE-INDUCED ANTIBODIES TO NATIVE AND RECOMBINANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEINS, Vaccine, 12(10), 1994, pp. 912-918
Authors:
BELSHE RB
GRAHAM BS
KEEFER MC
GORSE GJ
WRIGHT P
DOLIN R
MATTHEWS T
WEINHOLD K
BOLOGNESI DP
SPOSTO R
STABLEIN DM
TWADDELL T
BERMAN PW
GREGORY T
IZU AE
WALKER MC
FAST P
Citation: Rb. Belshe et al., NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZEDWITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1, JAMA, the journal of the American Medical Association, 272(6), 1994, pp. 475-480
Authors:
GRAHAM BS
GORSE GJ
SCHWARTZ DH
KEEFER MC
MCELRATH MJ
MATTHEWS TJ
WRIGHT PF
BELSHE RB
CLEMENTS ML
DOLIN R
COREY L
BOLOGNESI DP
STABLEIN DM
ESTERLITZ JR
HU SL
SMITH GE
Citation: Bs. Graham et al., DETERMINANTS OF ANTIBODY-RESPONSE AFTER RECOMBINANT GP160 BOOSTING INVACCINIA-NAIVE VOLUNTEERS PRIMED WITH GP160-RECOMBINANT VACCINIA VIRUS, The Journal of infectious diseases, 170(4), 1994, pp. 782-786
Authors:
GORSE GJ
SCHWARTZ DH
GRAHAM BS
MATTHEWS TJ
STABLEIN DM
FREY SE
BELSHE RB
CLEMENTS ML
WRIGHT PF
EIBL M
FAST PE
Citation: Gj. Gorse et al., HIV-1 RECOMBINANT GP160 VACCINE GIVEN IN ACCELERATED DOSE SCHEDULES, Clinical and experimental immunology, 98(2), 1994, pp. 178-184
Authors:
BELSHE RB
CLEMENTS ML
KEEFER MC
GRAHAM BS
COREY L
SPOSTO R
WESCOTT S
LAWRENCE D
GORSE GJ
KENNEDY D
FREY S
LAMBERT J
SCHWARTZ D
DOLIN R
ROBERTS N
MCELRATH J
COOMBS J
WRIGHT P
KARZON D
FAST P
WALKER MC
MESTECKY J
JACKSON S
STABLEIN D
WOLFF M
Citation: Rb. Belshe et al., INTERPRETING HIV SERODIAGNOSTIC TEST-RESULTS IN THE 1990S - SOCIAL RISKS OF HIV VACCINE STUDIES IN UNINFECTED VOLUNTEERS, Annals of internal medicine, 121(8), 1994, pp. 584
Authors:
BELSHE RB
CLEMENTS ML
DOLIN R
GRAHAM BS
MCELRATH J
GORSE GJ
SCHWARTZ D
KEEFER MC
WRIGHT P
COREY L
BOLOGNESI DP
MATTHEWS TJ
STABLEIN DM
OBRIEN FS
EIBL M
DORNER F
KOFF W
Citation: Rb. Belshe et al., SAFETY AND IMMUNOGENICITY OF A FULLY GLYCOSYLATED RECOMBINANT GP160 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VACCINE IN SUBJECTS AT LOW-RISK OF INFECTION, The Journal of infectious diseases, 168(6), 1993, pp. 1387-1395